Drug Profile
KHK 2898
Alternative Names: KHK2898Latest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD98 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 20 Apr 2016 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease) in Singapore (IV)
- 05 Mar 2015 Kyowa Hakko Kirin plans to re-initiate enrolment in its phase I trial in Solid tumours (Late-stage disease, Unresectable) in Singapore (NCT01516645)
- 06 May 2013 Kyowa Hakko Kirin suspends enrolment in its phase I trial in Solid tumours (Late-stage disease, Unresectable) in Singapore (NCT01516645)